Agilent Technologies: Early Signs Of Turnaround, But Not Cheap Enough
Summary: Agilent Technologies, a major player in life sciences and chemical analysis, faces cyclical and structural...
Tag: A
Agilent Q4: Expecting Market Recovery In 2025
Summary: I reiterate a “Buy” rating on Agilent Technologies, Inc. with a one-year target price of $150 per share,...
Agilent: A ‘Buy’ Due To Growing Biopharma, PFAS, And Semi
Summary: Agilent Technologies focuses on growing biopharma, PFAS testing, and advanced materials for semiconductors.Recent...
Agilent: Making A Move To Ignite Some Growth
Summary: Agilent Technologies shares looked appealing in 2023, trading at a reasonable 21 times forward earnings...
Agilent Hit By Cyclical Headwinds, But The Growth Story Remains Intact Long Term
Summary: Agilent's may be an underappreciated winner with Alnylam's recent clinical success, as manufacturing Amvuttra...
Is Agilent A Buy Before Earnings? Examining The Pros And Cons
Summary: Agilent Technologies is a major player in the diagnostics and research industry, with a focus on...
Agilent Technologies: Cash Flow Returns On Investments And Conventional All Point To A Hold
Summary: Agilent has reshuffled its portfolio and increased economic returns, but growth is expected to be sluggish, and...
Agilent Technologies Hit A Homerun
Summary: Agilent Technologies' Q4 revenue was $1.69 billion, reflecting a 9.7% YoY decline, but the company achieved a...
Agilent: A Wide Moat Company Expected To Return To Growth In 2024 (Rating Upgrade)
Summary: Agilent is a wonderful business with a strong competitive moat, decent growth, and excellent profitability.The...
Agilent Technologies: Looking Undervalued Heading Into Earnings
Summary: Agilent Technologies has a fantastic track record of strong EPS growth and outperforming capital gains.More...